Glycerol phenylbutyrate (Ravicti®) which is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/03/2018|
|Rapid review completed||20/06/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti®) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.|
The HSE has approved reimbursement; August 2018